IM Cannabis Corp. Files Resale Registration Statement for Securities Offerings

On June 9, 2026, IM Cannabis Corp. (commonly known as IMC) announced that it has filed a resale registration statement on Form F-3 with the Securities and Exchange Commission (SEC). This strategic move allows for the registration of approximately 17.3 million common shares, generating renewed interest among investors in the medical cannabis sector.

Details of the Resale Registration Statement

The registration includes shares related to three distinct convertible promissory notes issued between April and June 2026. The breakdown is as follows:

1. Convertible Promissory Note dated April 6, 2026: This note, valued at $250,000, allows the conversion of up to 4 million common shares.
2. Convertible Promissory Note dated May 7, 2026: Another note for $300,000 registers 6.72 million common shares for conversion.
3. Convertible Promissory Note dated June 3, 2026: The final note, outlined with principal of $225,000, offers the conversion of approximately 4.375 million common shares.

In addition to these notes, the registration includes shares from purchase warrants attached to the issuance of the promissory notes, which allow further conversions into common shares for a total reaching over 17 million shares.

The public will be able to view the full Resale Registration Statement once the SEC has processed the filing and it becomes effective. Interested shareholders have the potential to resell these securities using the associated prospectus, should they choose to do so. However, it is crucial to note that IM Cannabis Corp. will not receive any proceeds from these sales, as the transactions will solely be between the selling shareholders and the market.

Company Background

IM Cannabis Corp. operates in the burgeoning field of medical cannabis from its bases in Israel and Germany. The company is dedicated to building and scaling innovative cannabis business solutions, having established a comprehensive platform that includes distribution and retail pharmacy operations. In Israel, IMC manages a network of subsidiaries that efficiently import and distribute medically-approved cannabis, utilizing extensive proprietary data to guarantee quality and safety across its product offerings. Additionally, in Germany, IMC operates through its subsidiary Adjupharm GmbH, catering to local pharmacy needs for medical cannabis products.

Given the evolving landscape of cannabis regulation and market acceptance in various jurisdictions, IMC remains poised for further growth. The company is also actively considering potential opportunities to expand into other technology-driven sectors that align with its core competencies and operational expertise.

Looking Ahead

The future of IM Cannabis Corp. seems brightly illuminated by new possibilities as it navigates the regulatory framework associated with its latest filing. By successfully executing this resale of shares, IMC may enhance its resources and credibility within the medical cannabis industry. Furthermore, as legislation continues to evolve, the demand for medical cannabis solutions is expected to rise, ultimately benefiting innovative companies like IMC.

Investors and market enthusiasts alike will want to monitor the SEC's response to the Resale Registration Statement, which could open up additional avenues for investment and share trading within the lucrative medical cannabis sector. For any updates on this press release and subsequent events, potential investors should stay informed through the company's profile on platforms like SEDAR+ and SEC's Edgar system.